Clinical trials: Thrombin, open to volunteers
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Hemorrhagic Disorders
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage
Primary purpose : Compare the sensitivity of several thromboplastin reagents of various origins to prothrombin time and factor II, V, VII and X assays in two different populations of patients : Patients with an isolated extrinsic…
- Trial name
- RHEOMICS (NCT06974396)
- Testing
- Prothrombin time
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Healthy Individuals (Controls), Vascular Surgery Patients With Acute Thrombosis
Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients
Primary Objective: To develop a thrombotic event risk assessment model integrating serum biomarkers (TM, TAT, t-PAIC, PIC) with clinical data, systematically compare its predictive performance across healthy populations, vascular…
- Conditions
- Healthy Individuals (Controls), Vascular Surgery Patients With Acute Thrombosis, Dialysis Patients
- Trial name
- TAT-t-PAIC (NCT07098676)
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Ai Peng
Liver Cirrhosis
DOAC in Patients with Child a or B Liver Cirrhosis
The goal of this clinical trial is to investigate pharmacokinetics and pharmacodynamics of direct oral anticoagulant drugs (DOAC), specifically apixaban and edoxaban, in patients with Child A or B liver cirrhosis (LC).
- Trial name
- CIRROAC (NCT05869591)
- Testing
- Apixaban 5 MG [Eliquis], Edoxaban 60 MG [Lixiana]
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Fibrin Blood Clot, Pregnancy
Pregnancy and Fibrin Clot Properties
1. The structure of fibrin clot and thrombin generation may vary between trimesters of pregnancy. 2. Unfavorably altered fibrin clot properties along with enhanced thrombin generation may lead to the development of complications…
- Conditions
- Fibrin Blood Clot, Pregnancy, Pregnancy Complicated by Cardiovascular Disorders as Postpartum Condition, Delivered During Previous Episode
- Trial name
- NCT07275476
- Testing
- analysis of fibrin clot properties and thrombin generation
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Jagiellonian University
Cancer, Pulmonary Embolism
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of…
- Conditions
- Cancer, Pulmonary Embolism, Thrombosis
- Trial name
- CATforCAT (NCT06386107)
- Testing
- Thrombin Generation Assay (TGA)
- Where
- 4 sites in France
- Volunteers
- 212 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Burns, Skin Graft Complications
Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft
Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base.
- Trial name
- NCT06379724
- Testing
- Tranexamic acid, Thrombin JMI, skin graft
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Kansas Medical Center
Venous Thromboembolism, Cancer
Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study
Cancer patients are at higher risk of getting a blood clot (known as venous thromboembolism (VTE)) especially during chemotherapy and some patients are more at risk than others.
- Trial name
- PINPOINT (NCT07196020)
- Where
- 3 sites in Ireland
- Volunteers
- 380 people
- Sponsor
- University of Dublin, Trinity College
Gastrointestinal Bleeding
Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants
Gastrointestinal bleeding (GIB) is a common emergency in hepatology and gastroenterology, with an overall mortality rate ranging from 5% to 10% depending on the study.
- Trial name
- HEMOD-AOD (NCT07333144)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Myeloma, Total Knee Replacement
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis.
- Trial name
- ProApix (NCT06474182)
- Testing
- Blood sampling, Apixaban
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Solid Carcinoma
Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk
Coagulation is a complex system which, through the action of thrombin, leads to the formation of fibrin, which stabilises the platelet clot.
- Trial name
- THROMBIN (NCT06051214)
- Testing
- thrombogram
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Cancerologie de l'Ouest
Blood Coagulation Disorders, Inherited, Thrombotic Disorder
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
The objective of this study will be to assess the coagulation system in-vitro in a variety of bleeding and clotting disorders using the ROTEG analyzer and the thrombin generation assay.
- Trial name
- NCT00178594
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- The University of Texas Health Science Center, Houston
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Isoquercetin in People With Ovarian Cancer
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Serous Ovarian Tumor
- Trial name
- NCT07303894
- Testing
- Isoquercetin
- Where
- 8 sites in United States
- Volunteers
- 90 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hemophilia, Inhibitors
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
This study is a multicenter, prospective, single-arm exploratory clinical trial designed to evaluate the efficacy and safety of prothrombin complex concentrate (PCC) in the treatment of bleeding episodes in patients with…
- Trial name
- 2022PCC-A (NCT07406139)
- Testing
- PCC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Device-detected Atrial Fibrillation, Subclinical Atrial Fibrillation
Blood Clotting Markers and Heart Ultrasound in People With Device-Detected Atrial Fibrillation
The purpose of this observational study is to investigate whether blood tests related to blood clotting are associated with established clinical stroke risk scores, the total amount of device-detected atrial fibrillation recorded…
- Conditions
- Device-detected Atrial Fibrillation, Subclinical Atrial Fibrillation, Atrial High Rate Episodes
- Trial name
- DDAF-HEV (NCT07713615)
- Where
- Denmark
- Volunteers
- 222 people
- Sponsor
- Andreas Sjøholm-Christensen
Hemophilia
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Background The treatment of haemophilia A and B has been revolutionized by the use of factor concentrate, both as prophylaxis and to treat bleeding episodes (on-demand treatment).
- Trial name
- NCT02453542
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska Institutet
Cardiac Valve Disease
Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery
The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for cardiac…
- Trial name
- NCT06144125
- Testing
- fresh frozen plasma, prothrombin complex concentrate
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Konkuk University Medical Center
Factor V Leiden, Prothrombin G20210A
Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations
This study will enrol individuals who have, or may have, Factor V Leiden or Prothrombin G20210A mutations, which are genetic changes linked to an increased risk of blood clots.
- Trial name
- NCT07584265
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Richmond Research Institute
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
This is a phase 3, multicenter, randomized, open-label, parallel-group, controlled study to assess the efficacy and safety of BE1116 compared with fresh frozen plasma (FFP) in adult participants undergoing complex cardiovascular…
- Trial name
- NCT07094087
- Testing
- BE1116, FFP
- Where
- 24 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- CSL Behring
Uterine Prolapse, Urine Incontinence
The Assessment of Fibrin Clot Phenotype and Thrombin Generation in Women After Urogynecological Surgeries.
Determination of fibrin clot properties along with thrombin generation in women after urigynecological surgery.
- Trial name
- NCT07295782
- Testing
- determination of fibrin clot properties
- Where
- Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jagiellonian University